Endocrinology

Beta Bionics plans to launch Mint through the pharmacy channel in the first quarter of 2027.

Diana Isaacs, PharmD, and Natalie Bellini, DNP, unpack tirzepatide's new CV indication and the STAREE statin trial in older adults.

SURPASS-CVOT showed tirzepatide is non-inferior to dulaglutide for cardiovascular events in more than 13,000 adults with type 2 diabetes.

In this episode of Diabetes Dialogue, co-hosts Diana Isaacs, PharmD, and Natalie Bellini, DNP, are joined by Casey Halpern, MD, to discuss SynchNeuro's investigational, non-invasive EEG-based glucose monitor.

In this episode, co-hosts Isaacs and Bellini are joined by Eden Miller, DO, and Davida Kruger, NP, to discuss the FDA's recent clearance of the FreeStyle Libre Duo ketone monitor.

Abbott's Libre Duo 10 Day earned FDA De Novo authorization, becoming the first continuous dual glucose-ketone monitor for diabetes.

This episode discusses the recent results from trials of IcoSema and a new highly concentrated insulin aspart.

Stay updated with the latest healthcare breakthroughs, including a new lerodalcibep FDA approval and phase 3 avexitide data in post-bariatric hypoglycemia.

The phase 3 trial showed a 55% reduction in Level 2 and Level 3 hypoglycemic events versus placebo, meeting all secondary endpoints.

Novo Nordisk's once-weekly insulin icodec-abae (Awiqli) has launched nationwide for adults with type 2 diabetes.

Diabetes Dialogue hosts recap ADCES26 highlights on insulin delivery tech, CKM care, C-peptide science, ketone monitoring, and hypercortisolism screening.

In a trial comparing tirzepatide initiation with sitagliptin, the GLP-1/glucose dual agonist displayed greater reductions in major cardiovascular events.

Limits to provider taxes used to fund Medicaid programs, as well as increased eligibility requirements and cost-sharing obligations, may make insurance inaccessible.

Combination therapy with navepegritide and lonapegsomatropin has demonstrated its efficacy in improving mean annualized growth velocity in pediatric patients.

In this segment from the latest episode of Diabetes Dialogue, cohosts Natalie Bellini, DNP, and Diana Isaacs, PharmD, discuss the topline results of the TRIUMPH-2 trial of retatrutide.

Diabetes Dialogue cohosts Diana Isaacs, PharmD, and Natalie Bellini, DNP, discuss the risks of ordering GLP-1 RAs online.

Anderson discusses recent advancements in CGM technology, as well as the myriad behavioral and clinical benefits of CGM use in T2D with or without insulin.

New Drug Applications and key trial readouts punctuated July for endocrinology, with treatments for hypocalcemia, diabetes, and more.

A recent study from Kaiser Permanente has indicated substantial HbA1c improvements among patients receiving food-based support.

Retatrutide met 80-week weight-loss endpoints in TRIUMPH-2 and TRIUMPH-3, prompting a planned FDA submission in Q1 2027.

If approved, encaleret will be the first treatment specifically indicated for this underrepresented patient population.

Ashish Rana, MD, discusses Sermo’s recent clinician survey, which highlighted patients’ use of unapproved and compounded GLP-1 medications.

FDA accepted Camurus’ resubmitted CAM2029 application for acromegaly, with a target action date of December 18, 2026.

Phase 3 FIND-CKD data show finerenone slows kidney decline and reduces CV events in adults with nondiabetic CKD, Rajiv Agarwal, MD, adds his perspective.

New data from the 45-patient Midpoint Cohort, despite not being powered for statistical significance, indicate a potentially substantial benefit.